A phase II study of the docetaxel-carboplatin chemotherapy regimen in advanced non-small-cell lung cancer

Lung

Volumn 183, Issue 6, 2005, Pages 405-416

  Tsavaris, Nicolas ^a,e   Kosmas, Christos ^b   Skopelitis, Elias ^a   Gennatas, Kostantinos ^c   Zorbala, Alexandra ^a   Papas, Paris ^a   Gouveris, Panagiotis ^a   Antypas, George ^d   Rokana, Sofia ^a   Tzelepis, George ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d Sixth Pulmonary Clinic   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Carboplatin; Docetaxel; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; METHYLPREDNISOLONE; ONDANSETRON; PACLITAXEL; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLATULENCE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 32244432207     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-005-2552-5     Document Type: Article

References (30)

1. Bando H, Miyata J, Sano T, Sumitomo M (2001a) Retrospective analysis of administration of a combination of docetaxel and carboplatin for advanced non-small cell lung cancer. Anticancer Res 21:2107-2113
2. Bando H, Miyata J, Sano T, Sumitomo M (2001b) Combination chemotherapy of carboplatin and docetaxel for advanced non-small cell lung cancer (NSCLC). Gan to Kagaku Ryoho 28:947-952
3. Belani CP (1997) Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology (Huntingt) 11(Suppl 8):42-45
4. Belani C, Lynch T (2001) Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management. Semin Oncol 28(Suppl 2):10-14
5. Belani CP, Einzig A, Bonomi P, et al. (2000) Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 11:673-678
6. Bonomi PD, Finkelstein DM, Ruckdeschel JC, et al. (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613
7. Comer AM, Goa KL (2001) Docetaxel: a review of its use in non-small cell lung cancer. Drugs Aging 17:53-80
8. Cox DR (1970) The analysis of binary data Methuen, London
9. Fossella FV, De Vore R, Kerr RN, et al. (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362
10. Fossella F, Pereira JR, von Pawel J, et al. (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016-3024
11. Gandara DR, Edelman MJ, Lau D (1999) Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol 26(Suppl) 10:3-7
12. Giaccone G, Splinter TAW, Debruyne C, et al. (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. J Clin Oncol 16:2133-2141
13. Giannakakis T, Ziras N, Kakolyris S, et al. (2000) Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. Eur J Cancer 36:742-747
14. Giannakakis T, Kakolyris S, Theodoropoulos E, et al. (2002) A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res 22:3743-3748
15. Green MR (2001) The current status of docetaxel for advanced non-small cell lung cancer. Anticancer Drugs 12(Suppl 1):S11-S16
16. Herse B, Dalichau H, Wormann B, et al. (1998) Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. Thorac Cardiovasc Surg 46:298-302
17. Jahanzeb M, Sarna G, Hirsch R, et al. (2004) Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res 24:1239-1242
18. Kaplan EL, Meier P (1959) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
19. Kasahara K, Myo S, Iwasa K, et al. (2002) A phase I study of carboplatin and docetaxel for advanced non-small cell lung cancer using the continual reassessment method. Jpn J Clin Oncol 32:512-516
20. Kosmas C, Tsavaris N, Polyzos A, et al. (2000) A phase II study of paclitaxel-ifosfamide-cisplatin (PIC) combination in advanced non-small cell lung cancer. Cancer 89:774-782
21. Kosmas C, Tsavaris NB, Makatsoris T, et al. (2002) A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Int J Cancer 98:141-147
22. Laack E, Dierlamm T, Knuffmann C, et al. (2002) Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer 36:303-307
23. Millward MJ, Boyer MJ, Lehnert M, et al. (2003) Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 14:449-454
24. Non-small Cell Lung Cancer Cooperative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909
25. Oka M, Fukuda M, Nagashima S, et al. (2001) Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48:446-450
26. Ornstein DL, Rigas JR (1998) Taxotere: clinical trials in non-small cell lung cancer. Oncologist 1998;3:86-93
27. Ramalingam S, Dobbs TW, Einzig AI, et al. (2004) Carboplatin and docetaxel in advanced non-small cell lung cancer: results of a multicenter phase II study. Cancer Chemother Pharmacol 53:439-444
28. Shepherd FA, Dancey J, Ramlau R, et al. (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2101
29. Tsavaris N, Fountzilas G, Mylonakis N (1998) A randomized comparative study of antiemetic prophylaxis with ondansetron in a single 32 mg loading dose vs 8 mg every six hours, in patients under cisplatin-based chemotherapy. Oncology 55:513-516
30. Zarogoulidis K, Kontakiotis T, Hatziapostolou P, et al. (2001) A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 32:281-287